Posted by Michael Wonder on 01 Aug 2024
CHMP recommends Rybrevant (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR mutated non-small cell lung cancer after failure of prior therapy
31 July 2024 - CHMP recommends Rybrevant (amivantamab) in combination with chemotherapy for the treatment of adult patients with advanced EGFR-mutated non-small cell lung cancer after failure of prior therapy.
Janssen-Cilag International today announced that the CHMP of the EMA has recommended the approval of a type II extension of indication for Rybrevant (amivantamab) in combination with chemotherapy (carboplatin and pemetrexed), for the treatment of adult patients with advanced non-small cell lung cancer with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations, after failure of prior therapy including an EGFR tyrosine kinase inhibitor.
